AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9974084 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 7780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Rubber (RR) double-lumen tubes
Number of subjects: 21
Study 7780066 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl-Chloride (PVC) double-lumen tubes
Number of subjects: 21
Study 7780066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RR and PVC groups
Number of subjects: 21
Study 1699704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol DA-20% (FDA)
Number of subjects: 46
Study 1699704 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid/hydroxyethyl starch (CHS)
Number of subjects: 46
Study 362094 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrrolate (0.5% and 1.0%)
Number of subjects: 129
Study 362094 — intervention group
Group type: COMPARATOR
Intervention: Topical scopolamine
Number of subjects: 129
Study 362094 — intervention group
Group type: COMPARATOR
Intervention: Commercial topical antiperspirants
Number of subjects: 129
Study 29983135 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 40 days
Number of subjects: 54
Study 29983135 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 75 days
Number of subjects: 54
Study 29983135 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed diet (LS) containing 10% whole linseed, fed for 120 days
Number of subjects: 54
Study 29983135 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 40 days
Number of subjects: 54
Study 29983135 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 75 days
Number of subjects: 54
Study 29983135 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CO) with no supplemental fat, fed for 120 days
Number of subjects: 54
Study 26011652 — intervention group
Group type: EXPERIMENTAL
Intervention: BHOMA intervention
Number of subjects: 0
Study 25563737 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein-enriched preload beverage (300 ml, 1300 kJ, 45 g)
Number of subjects: 18
Study 25563737 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin carbohydrate-enriched preload beverage
Number of subjects: 18
Study 23926573 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-37822681 (10 mg, 20 mg, or 30 mg, twice daily)
Number of subjects: 0
Study 23926573 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10 mg/d during week 1; 15 mg/d after week 1)
Number of subjects: 0
Study 23926573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks followed by 6 weeks of olanzapine, 15 mg/d)
Number of subjects: 0
Study 22136031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz continuous wave (Group B)
Number of subjects: 80
Study 22136031 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz continuous wave (Group C)
Number of subjects: 80
Study 22136031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz/100 Hz (Group D)
Number of subjects: 80
Study 22136031 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 80
Study 22136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 80
Study 22136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 80
Study 19594251 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicultural training program
Number of subjects: 86
Study 19594251 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocultural training program
Number of subjects: 86
Study 19594251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 86
Study 19594251 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer research training programs (both multicultural and monocultural)
Number of subjects: 86
Study 16738292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator guided pudendal nerve block
Number of subjects: 80
Study 16738292 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study 15301641 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power child component
Number of subjects: 0
Study 15301641 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Coping Power Program with parent and child components
Number of subjects: 0
Study 15301641 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 11051229 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid preparation of DFMO at daily dose 0.5 gram/m2
Number of subjects: 10
Study 11051229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet preparation of DFMO at daily dose 0.5 gram/m2
Number of subjects: 10
Study 9349514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle capillary biopsy (FNCB)
Number of subjects: 50
Study 9349514 — intervention group
Group type: COMPARATOR
Intervention: Fine-needle aspiration biopsy (FNAB)
Number of subjects: 50
Study 7693506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg via metered dose inhaler)
Number of subjects: 6
Study 7693506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7693506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 6
Study 4041951 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes before premedication
Number of subjects: 74
Study 4041951 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking group (not allowed to smoke)
Number of subjects: 74
Study 30794237 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandage
Number of subjects: 51
Study 28472255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified antituberculosis regimen (15 mg/kg/day rifampicin and 20 mg/kg/day levofloxacin for the first 8 weeks)
Number of subjects: 322
Study 28472255 — intervention group
Group type: COMPARATOR
Intervention: Standard 9-month antituberculosis regimen (10 mg/kg/day rifampicin)
Number of subjects: 322
Study 25937380 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 102
Study 25937380 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 102
Study 25937380 — intervention group
Group type: EXPERIMENTAL
Intervention: AirTraq
Number of subjects: 102
Study 25937380 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller Laryngoscope
Number of subjects: 102
Study 23871105 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet quality
Number of subjects: 177
Study 23871105 — intervention group
Group type: EXPERIMENTAL
Intervention: Child diet quality
Number of subjects: 177
Study 23871105 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 177
Study 21190026 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 463
Study 21190026 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 463
Study 19222654 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (Medihoney)
Number of subjects: 105
Study 19222654 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 105
Study 17133774 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2‐7)
Number of subjects: 202
Study 17133774 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 202
Study 12642564 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported home safety practices (using smoke alarms, stair gates, syrup of ipecac)
Number of subjects: 0
Study 12642564 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11227970 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 154
Study 11227970 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 154
Study 9513096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract with Prime and Bond 2.0 (Group 2)
Number of subjects: 4
Study 9513096 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass with Syntac Single Component (Group 4)
Number of subjects: 4
Study 9513096 — intervention group
Group type: COMPARATOR
Intervention: Dyract with Dyract‐PSA primer (Group 1)
Number of subjects: 4
Study 9513096 — intervention group
Group type: COMPARATOR
Intervention: Compoglass with SCA primer (Group 3)
Number of subjects: 4
Study 7845561 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning tasks including a three-dimensional motor problem and two standard precision tests.
Number of subjects: 20
Study 7845561 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (16 subjects).
Number of subjects: 20
Study 3395307 — intervention group
Group type: EXPERIMENTAL
Intervention: Feingold diet (6 weeks)
Number of subjects: 55
Study 3395307 — intervention group
Group type: COMPARATOR
Intervention: Synthetic food colourings (50 mg of tartrazine or carmoisine for 2 weeks each)
Number of subjects: 55
Study 3395307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during lead-in and washout periods)
Number of subjects: 55
Study 31339245 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics (LAI AP)
Number of subjects: 0
Study 31339245 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics
Number of subjects: 0
Study 28803535 — intervention group
Group type: EXPERIMENTAL
Intervention: High robotic assistance (82% success at hitting targets)
Number of subjects: 30
Study 28803535 — intervention group
Group type: COMPARATOR
Intervention: Low robotic assistance (55% success at hitting targets)
Number of subjects: 30
Study 28803535 — intervention group
Group type: EXPERIMENTAL
Intervention: High robotic assistance
Number of subjects: 30
Study 28803535 — intervention group
Group type: COMPARATOR
Intervention: Low robotic assistance
Number of subjects: 30
Study 28803535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high and low robotic assistance
Number of subjects: 30
Study 24566799 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 74
Study 24566799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23892047 — intervention group
Group type: EXPERIMENTAL
Intervention: C3a priming of UCB unit
Number of subjects: 30
Study 23892047 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 30
Study 21478739 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel user interface
Number of subjects: 20
Study 21478739 — intervention group
Group type: COMPARATOR
Intervention: Standard electronic medical record
Number of subjects: 20
Study 19170461 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure (maximum of three 2-hr sessions during 1 week)
Number of subjects: 10
Study 19170461 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure
Number of subjects: 10
Study 16498159 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 259
Study 16498159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 259
Study 12724018 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (group A)
Number of subjects: 70
Study 12724018 — intervention group
Group type: COMPARATOR
Intervention: Calcium (group B)
Number of subjects: 70
Study 10392347 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17
Study 10392347 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 17
Study 11951458 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring cerebral blood flow, arteriovenous difference of oxygen, saturation of jugular venous blood flow with oxygen, and cerebral metabolic rate of oxygen
Number of subjects: 0
Study 1859004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil
Number of subjects: 24
Study 1859004 — intervention group
Group type: COMPARATOR
Intervention: Epidural alfentanil
Number of subjects: 24
Study 1859004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (iv and epidural)
Number of subjects: 24
Study 6345478 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum granules, 15 g/d for 3 months
Number of subjects: 12
Study 6345478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6345478 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum granules
Number of subjects: 12
Study 31144308 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring for Children Through Conflict and Displacement intervention
Number of subjects: 120
Study 31323048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 35
Study 31323048 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 35
Study 28551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40
Study 28551083 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 26150193 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 680
Study 26150193 — intervention group
Group type: COMPARATOR
Intervention: First-generation drug-eluting stent
Number of subjects: 680
Study 23341895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warning labels
Number of subjects: 3371
Study 23341895 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning labels
Number of subjects: 3371
Study 21928127 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MgSO(4) plus 15 mg bupivacaine 0.5%
Number of subjects: 79
Study 21928127 — intervention group
Group type: COMPARATOR
Intervention: 15 mg bupivacaine 0.5% with 0.2 ml normal saline (control group)
Number of subjects: 79
Study 18256870 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 22
Study 18256870 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 22
Study 17024872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous transplants followed by maintenance therapy
Number of subjects: 5000
Study 17024872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential autologous transplants followed by nonmyeloablative allotransplants
Number of subjects: 5000
Study 17024872 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction and/or consolidation treatments
Number of subjects: 5000
Study 17024872 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted transplant approaches
Number of subjects: 5000
Study 17024872 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional myeloablative allogeneic transplants
Number of subjects: 5000
Study 15022177 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum extracts with 50-60 mg harpagoside daily
Number of subjects: 0
Study 15022177 — intervention group
Group type: COMPARATOR
Intervention: Proprietary ethanol extract with lower harpagoside dosage
Number of subjects: 0
Study 10893344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Number of subjects: 18
Study 10893344 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Number of subjects: 18
Study 10893344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 18
Study 8846752 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 46
Study 8846752 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study 1352567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 22071
Study 1352567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 6090014 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2 iv every 3 weeks) and Mitomycin (12 mg/m2 iv every 6 weeks)
Number of subjects: 77
Study 6090014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2 iv every 3 weeks X 3, then every 6 weeks) and Etoposide (80 mg/m2 iv on Days 1‐3 every 3 weeks X 3, then every 6 weeks)
Number of subjects: 77
Study 3538450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (Clinoril; Frosst‐MSD)
Number of subjects: 30
Study 3538450 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study 29368658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy (LASH)
Number of subjects: 0
Study 29368658 — intervention group
Group type: COMPARATOR
Intervention: Second generation endometrial ablation (EA)
Number of subjects: 0
Study 27914499 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised combined endurance and resistance exercise
Number of subjects: 30
Study 27914499 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 30
Study 24166510 — intervention group
Group type: COMPARATOR
Intervention: Control drink (CR)
Number of subjects: 22
Study 24166510 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Ration drink (CRHR)
Number of subjects: 22
Study 22410021 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg per hr after an induction bolus of 2 mg/kg)
Number of subjects: 19
Study 22410021 — intervention group
Group type: COMPARATOR
Intervention: Control group (midazolam 0.2 mg/kg for induction without intravenous anesthetic infusion for maintenance)
Number of subjects: 19
Study 20709767 — intervention group
Group type: EXPERIMENTAL
Intervention: Google
Number of subjects: 0
Study 20709767 — intervention group
Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 0
Study 20709767 — intervention group
Group type: COMPARATOR
Intervention: PubMed
Number of subjects: 0
Study 20709767 — intervention group
Group type: COMPARATOR
Intervention: Ovid
Number of subjects: 0
Study 20709767 — intervention group
Group type: EXPERIMENTAL
Intervention: Google and UpToDate
Number of subjects: 0
Study 18215542 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating and drinking while driving
Number of subjects: 0
Study 18215542 — intervention group
Group type: COMPARATOR
Intervention: Normal driving
Number of subjects: 0
Study 15993354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment
Number of subjects: 153
Study 15993354 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic treatment
Number of subjects: 153
Study 12544527 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 61
Study 12544527 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ferguson procedure
Number of subjects: 61
Study 10655925 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask size 5 (males)
Number of subjects: 63
Study 10655925 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask size 4 (females)
Number of subjects: 63
Study 8918002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempe-yellow maize porridge (TYMP)
Number of subjects: 117
Study 8918002 — intervention group
Group type: COMPARATOR
Intervention: Milk-yellow maize porridge (MYMP)
Number of subjects: 117
Study 1887741 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion group (N = 38)
Number of subjects: 80
Study 1887741 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 42)
Number of subjects: 80
Study 6348485 — intervention group
Group type: EXPERIMENTAL
Intervention: Opipramol (50 mg sugar-coated tablets)
Number of subjects: 48
Study 6348485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6348485 — intervention group
Group type: EXPERIMENTAL
Intervention: Opipramol
Number of subjects: 48
Study 31538305 — intervention group
Group type: EXPERIMENTAL
Intervention: Macuprev Supplementation
Number of subjects: 0
Study 31538305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29487223 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus carboplatin, paclitaxel, and bevacizumab (Arm A)
Number of subjects: 25
Study 29487223 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin, paclitaxel, and bevacizumab without metformin (Arm B)
Number of subjects: 25
Study 26655368 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band (WSEB) group‐exercises, conducted three times per week for 40 minutes per session, first six months volunteer-led, followed by six months DVD-guided.
Number of subjects: 127
Study 26655368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 127
Study 26655368 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band (WSEB) group‐exercises.
Number of subjects: 127
Study 25041441 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival air-polishing with erythritol powder containing 0.3% chlorhexidine
Number of subjects: 50
Study 25041441 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic debridement
Number of subjects: 50
Study 25041441 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival air-polishing
Number of subjects: 50
Study 21805085 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon (micronised purified flavonoid fraction)
Number of subjects: 40
Study 21805085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20723640 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 440
Study 20723640 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 440
Study 20723640 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 440
Study 20723640 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-9
Number of subjects: 440
Study 20723640 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker strategy including interleukin-6, B-type natriuretic peptide, aldosterone, and matrix metalloproteinase-9
Number of subjects: 440
Study 17650271 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 118
Study 17650271 — intervention group
Group type: COMPARATOR
Intervention: Standard community mental health care
Number of subjects: 118
Study 16537213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination device involving radiofrequency, infrared light, and mechanical suction-based massage (20 watts RF, 20 watts IR, 200 millibar vacuum)
Number of subjects: 20